UK Companies House feature
NAPP PHARMACEUTICAL GROUP LIMITED
Profile
- Company number
- 00884285
- Status
- Active
- Incorporation
- 1966-07-27
- Last accounts made up
- 2024-12-31
- Account category
- FULL
- Primary SIC
- 21200
- Hubs
- UK Healthcare
Accounts
Pending extraction
Audit & accounting basis
From AI-extracted PDF accounts
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Ernst & Young LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The Company's business activities, together with the factors likely to affect its future development, are described in the Strategic Report. The Company is a member of the Napp Pharmaceutical Holdings Limited group, and is subject to the overall financing arrangements of the group. As such the Company has received a formal letter of support from the Company's parent undertaking, guaranteeing continued financial support to enable the Company to meet its liabilities to creditors as they fall due for the period to 31 August 2026. The directors have assessed that the group has sufficient resources to provide such support notwithstanding the risks and uncertainties disclosed in the group consolidated financial statements. The Company, through its group activities, expects to see continued demand for its product portfolio, which notably contains many well-established products treating chronic conditions. The group's latest financial projections show that the group remains in a strong position to support the Company through to 31 August 2026. Based on this assessment the directors continue to adopt the going concern basis in preparing the annual report and accounts.”
Subsidiaries
- Napp Laboratories Limited · 100% held · supply of pharmaceutical products
- Bard Pharmaceuticals Limited · 100% held · manufacture of pharmaceutical products
- Napp Research Centre Limited · 100% held · non-trading
Significant events
- “On 24 April 2024, the Company acquired all of Cidara Therapeutic's rights related to Rezafungin globally for nil consideration. The Company acquired the rights to future royalties and milestone payments as well as the obligations to fund ongoing development costs. The fair value of net assets acquired was £51,278,000 resulting in negative goodwill of £51,278,000.”
- “On 8 August 2024, the board agreed to extend the unsecured loan of $43.5m to a related party to 14 November 2024 and amend the interest rate to 5.83% per annum. The amendments became effective on 14 August 2024. The loan was subsequently repaid on 15 November 2024.”
- “On 02 July 2025, the Board of the Company declared an interim dividend distribution of $6,583 equivalent to £4,818.”
Auditor / going-concern / subsidiary information is extracted from the PDF version of the latest annual accounts and is not tagged in iXBRL. About these numbers
People
2 active · 23 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| JAMIESON, Stephen Johan | Director | 2019-02-22 | Sep 1957 | British |
| LEA, Bryan George | Director | 2020-01-01 | Jun 1961 | British |
Show 23 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| CORNHILL SERVICES LIMITED | Corporate Secretary | 2008-03-25 | 2009-02-26 |
| TIERCEL SERVICES LIMITED | Corporate Secretary | 2009-02-26 | 2018-06-11 |
| TIERCEL SERVICES LIMITED | Corporate Secretary | — | 2008-03-25 |
| BAKER, Stuart David | Director | 1994-12-08 | 2019-12-31 |
| MANNERS, Paul | Director | — | 2001-12-31 |
| MATTESSICH, Antony | Director | 2011-05-19 | 2017-07-31 |
| MERCER, Samuel D | Director | — | 1994-12-08 |
| MILLER, Ronald B | Director | — | 1997-12-31 |
| MITCHELL, Christopher Benbow | Director | — | 2018-04-12 |
| SACKLER, Beverly | Director | 1995-06-20 | 2017-10-17 |
| SACKLER, David Alex | Director | 2012-07-19 | 2018-06-11 |
| SACKLER, Jonathan David | Director | 1995-06-20 | 2018-06-11 |
| SACKLER, Kathe Anne, Dr | Director | 1995-06-20 | 2018-06-11 |
| SACKLER, Mortimer David | Director | 1995-06-20 | 2010-03-24 |
| SACKLER, Mortimer David Alfons | Director | 1995-06-20 | 2018-06-11 |
| SACKLER, Raymond Raphael | Director | 1995-06-20 | 2017-07-17 |
| SACKLER, Richard Stephen | Director | 1995-06-20 | 2018-06-11 |
| SACKLER, Theresa | Director | 1995-06-20 | 2018-06-11 |
| SACKLER HUNT, Samantha Sophia | Director | 1995-06-20 | 2017-10-17 |
| SACKLER LEFCOURT, Ilene | Director | 1995-06-20 | 2018-06-11 |
| WHITE, Jonathon Grenville | Director | 1999-03-26 | 2002-09-06 |
| WIKSTROM, Ake Gunnar | Director | 2018-04-12 | 2019-02-22 |
| WIKSTROM, Ake Gunnar | Director | 2001-09-05 | 2011-05-19 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Napp Pharmaceutical Holdings Limited | Corporate entity | Shares 75–100% | 2016-04-06 | Active |
Filing timeline
Last 20 of 214 total filings
| Date | Type | Category | Description |
|---|---|---|---|
| 2025-11-17 | CH01 | officers | change person director company with change date |
| 2025-09-09 | AA | accounts | accounts with accounts type full |
| 2025-05-29 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2025-02-06 | AD02 | address | change sail address company with old address new address |
| 2025-02-05 | AD01 | address | change registered office address company with date old address new address |
| 2024-12-12 | MR04 | mortgage | mortgage satisfy charge full |
| 2024-08-27 | AA | accounts | accounts with accounts type full |
| 2024-06-19 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2024-04-04 | CH01 | officers | change person director company with change date |
| 2023-10-16 | AA | accounts | accounts with accounts type full |
| 2023-06-14 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2022-12-14 | AA | accounts | accounts with accounts type full |
| 2022-07-04 | CH01 | officers | change person director company with change date |
| 2022-06-22 | AD02 | address | change sail address company with old address new address |
| 2022-06-21 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2022-02-01 | AA | accounts | accounts with accounts type full |
| 2021-07-19 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2021-01-08 | AA | accounts | accounts with accounts type full |
| 2020-10-06 | MA | incorporation | memorandum articles |
| 2020-10-06 | RESOLUTIONS | resolution | resolution |
Credit score
Altman Z″ — composite of working capital, retained earnings, EBIT, and leverage
Activity Score
Filings velocity, capital events, officer churn, accounts trajectory